| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
Neuraxis, INC
13D/A
NRXS · 64134X201
|
9.9% |
11/16/2026
Event 9/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
Delcath Systems, Inc.
13D/A
DCTH · 24661P807
|
9.9% |
10/19/2026
Event 10/13/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 4.5% | |||||
| Rosalind Opportunities Fund I L.P. | 4.9% | |||||
| Schedule 13G · 14 securities · passive | ||||||
|
Talphera, Inc.
13G/A
TLPH · 00444T209
|
9.9% |
11/13/2026
Event 9/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
Biofrontera Inc.
13G/A
BFRI · 09077D209
|
9.9% |
11/13/2026
Event 9/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
PolyPid Ltd.
13G/A
PYPD · M8001Q126
|
9.6% |
11/13/2026
Event 9/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.6% | |||||
| Salamon Steven A J | 9.6% | |||||
| Aharon Gil | 9.6% | |||||
| Rosalind Master Fund L.P. | 9.6% | |||||
|
MediWound Ltd.
13G/A
MDWD · M68830104
|
9.1% |
11/13/2026
Event 11/5/2026
|
||||
| Rosalind Advisors, Inc. | 9.1% | |||||
| Salamon Steven A J | 9.1% | |||||
| Aharon Gil | 9.1% | |||||
| Rosalind Master Fund L.P. | 9.1% | |||||
|
Myomo Inc.
13G/A
MYO · 62857J201
|
9.9% |
11/12/2026
Event 9/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
Femasys Inc
13G
FEMY · 31447E204
|
9.9% |
8/14/2026
Event 8/10/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
Regentis Biomaterials Ltd.
13G
001219096
|
9.9% |
8/13/2026
Event 6/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
Fennec Pharmaceuticals Inc.
13G/A
FENC · 31447P100
|
9.6% |
8/13/2026
Event 6/30/2026
|
||||
| Rosalind Advisors, Inc. | 9.6% | |||||
| Salamon Steven A J | 9.4% | |||||
| Aharon Gil | 9.4% | |||||
| Rosalind Master Fund L.P. | 9.2% | |||||
|
Kiora Pharmaceuticals, Inc.
13G/A
KPRX · 49721T101
|
9.9% |
2/11/2026
Event 12/31/2025
|
||||
| Rosalind Advisors, Inc. | 9.9% | |||||
| Salamon Steven A J | 9.9% | |||||
| Aharon Gil | 9.9% | |||||
| Rosalind Master Fund L.P. | 9.9% | |||||
|
InspireMD, Inc.
13G/A
NSPR · 45779A846
|
9.2% |
2/11/2026
Event 12/31/2025
|
||||
| Rosalind Advisors, Inc. | 9.2% | |||||
| Salamon Steven A J | 9.2% | |||||
| Aharon Gil | 9.2% | |||||
| Rosalind Master Fund L.P. | 8.3% | |||||
| Rosalind Opportunities Fund I L.P. | 1.0% | |||||
|
Cellectar Biosciences, Inc.
13G/A
CLRB · 15117F500
|
5.5% |
2/10/2026
Event 12/31/2025
|
||||
| Rosalind Advisors, Inc. | 5.5% | |||||
| Salamon Steven A J | 5.5% | |||||
| Aharon Gil | 5.5% | |||||
| Rosalind Master Fund L.P. | 4.1% | |||||
| Rosalind Opportunities Fund I L.P. | 1.4% | |||||
|
OptiNose, Inc.
13G/A
OPTN · 68404V209
|
0% |
8/11/2025
Event 6/30/2025
|
||||
| Rosalind Advisors, Inc. | 0% | |||||
| Salamon Steven A J | 0% | |||||
| Aharon Gil | 0% | |||||
| Rosalind Master Fund L.P. | 0% | |||||
|
Trevi Therapeutics, Inc.
13G/A
TRVI · 89532M101
|
1.2% |
2/13/2025
Event 2/13/2025
|
||||
| Rosalind Advisors, Inc. | 1.2% | |||||
| Salamon Steven A J | 1.2% | |||||
| Aharon Gil | 1.2% | |||||
| Rosalind Master Fund L.P. | 1.2% | |||||
|
Spruce Biosciences, Inc.
13G/A
SPRB · 85209E109
|
0% |
2/13/2025
Event 12/31/2024
|
||||
| Rosalind Advisors, Inc. | 0% | |||||
| Salamon Steven A J | 0% | |||||
| Aharon Gil | 0% | |||||
| Rosalind Master Fund L.P. | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.